Metotab

Methotrexate, the active ingredient in Metotab, is an antimetabolite presented as a tablet for oral use. It is employed to treat rheumatoid arthritis, psoriasis, certain leukemias and lymphomas, and to manage ectopic pregnancy.

GNH USA supplies Metotab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Metotab is manufactured under EU GMP guidelines, ensuring consistent potency and purity for clinical use.

Methotrexate is used in autoimmune and oncologic conditions that involve rapid cell proliferation or immune activation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and reduces scaling. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell growth. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Ectopic pregnancy: facilitates resolution of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: gastrointestinal upset that may include vomiting. - Mouth sores: painful ulceration of the oral mucosa. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe liver toxicity: potential hepatitis, fibrosis, or cirrhosis. - Pulmonary fibrosis: interstitial lung disease presenting with cough and dyspnea. - Bone marrow suppression: pancytopenia leading to infection risk and bleeding.

When using Methotrexate, several precautions should be observed to minimize risks.

- Monitor liver function: regular LFT testing recommended. - Assess blood counts: periodic CBC to detect cytopenias. - Avoid in pregnancy: contraindicated due to known teratogenicity (Category X). - Use effective contraception: both patients and partners must employ reliable methods throughout treatment and for several months after cessation. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Methotrexate interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - NSAIDs: can increase methotrexate plasma levels and toxicity. - Proton pump inhibitors: may reduce renal clearance and raise serum concentrations. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression risk. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: combined immunosuppression may increase infection risk. - Penicillins: may compete for renal tubular secretion, affecting methotrexate elimination. - Alcohol: can exacerbate hepatic toxicity.